Research programme: anticancer therapeutics - Schering-Plough/Amgen
Alternative Names: Anticancer therapeutics research programme - Schering-Plough/AmgenLatest Information Update: 21 Aug 2009
At a glance
- Originator Amgen; Schering-Plough
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Aug 2009 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 08 Sep 2008 Preclinical development is ongoing in USA
- 22 Feb 2005 NeoGenesis has been acquired and merged into Schering-Plough